The doses of 10 μg should replace the doses of 5 μg in newborn hepatitis B vaccination in China: A cost-effectiveness analysis

被引:16
作者
Yin, Juan [1 ]
Ji, Zhenhao [1 ]
Liang, Peifeng [1 ]
Wu, Qian [1 ]
Cui, Fuqiang [2 ]
Wang, Fuzhen [2 ]
Liang, Xiaofeng [2 ]
Zhuang, Guihua [1 ]
机构
[1] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Xian 710061, Shaanxi, Peoples R China
[2] Chinese Ctr Dis Control & Prevent, Beijing 100050, Peoples R China
关键词
Hepatitis B vaccine; Dose; Newborn; Cost-effectiveness analysis; Quality-adjusted life-year; VIRUS INFECTION; NATURAL-HISTORY; MATHEMATICAL-MODEL; HEPATOCELLULAR-CARCINOMA; ECONOMIC BURDEN; CHILDREN; IMMUNIZATION; ADOLESCENTS; STRATEGIES; PROTECTION;
D O I
10.1016/j.vaccine.2015.05.082
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To identify whether Chinese current series of three 5 mu g doses for newborn hepatitis B vaccination should be replaced by the series of three 10 mu g doses. Methods: A cost-effectiveness analysis was conducted from the societal perspective based on the constructed decision tree-Markov model. Model parameters were estimated from published literatures, government documents and our surveys. The expected cost and effectiveness were compared between the 3-dose 5 mu g series (the 5 mu g strategy) and the 3-dose 10 mu g series (the 10 mu g strategy), and the incremental cost-effectiveness ratio (ICER, additional cost per quality-adjusted life-years gained) was calculated. Threshold values of the efficacy difference of the two series for the ICER=0, 1 and 3 times per capita gross domestic product were analyzed under different scenarios to understand whether the 10 mu g strategy should replace the 5 mu g strategy according to the recommendation of World Health Organization. Results: The 10 mu g strategy would be cost-saving compared with the 5 mu g strategy under the base-case scenario. Under keeping all the other parameters at the base-case values or further adjusting any one of them to the value most unfavorable to the 10 mu g strategy, as long as the efficacy of 3-dose 10 mu g series was slightly higher than that of 3-dose 5 mu g series, the 10 mu g strategy would be cost-effective, highly cost-effective, or even cost-saving. Even under the most pessimistic scenario, i.e. all the other parameters, but the discount rate, at the values most unfavorable to the 10 p.g strategy, the 10 p..g strategy would be cost-effective if the efficacy difference reached higher than 1.23 percentage point. Conclusion: For newborn hepatitis B vaccination in China, the 10 mu g strategy should be cost-effective, even more possibly highly cost-effective or cost-saving compared with the current 5 mu g strategy. The doses of 10 mu g should be considered to replace the doses of 5 mu g in newborn hepatitis B vaccination in China. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3731 / 3738
页数:8
相关论文
共 50 条
  • [41] Cost-effectiveness Analysis of the National Perinatal Hepatitis B Prevention Program
    Barbosa, Carolina
    Smith, Emily A.
    Hoerger, Thomas J.
    Fenlon, Nancy
    Schillie, Sarah F.
    Bradley, Christina
    Murphy, Trudy V.
    PEDIATRICS, 2014, 133 (02) : 243 - 253
  • [42] Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis
    Araujo de Oliveira, Gustavo Laine
    Almeida, Alessandra Maciel
    da Silva, Anderson Lourenco
    Ruas Brandao, Cristina Mariano
    Gurgel Andrade, Eli Iola
    Cherchiglia, Mariangela Leal
    Acurcio, Francisco de Assis
    REVISTA DE SAUDE PUBLICA, 2013, 47 (04): : 769 - 780
  • [43] Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis
    Nayagam, Shevanthi
    Conteh, Lesong
    Sicuri, Elisa
    Shimakawa, Yusuke
    Suso, Penda
    Tamba, Saydiba
    Njie, Ramou
    Njai, Harr
    Lemoine, Maud
    Hallett, Timothy B.
    Thursz, Mark
    LANCET GLOBAL HEALTH, 2016, 4 (08): : E568 - E578
  • [44] Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China
    Li, Runqin
    Lin, Xiao
    Wang, Jing-Yue
    Wang, Xiaomo
    Lu, Junfeng
    Liu, Yali
    Cao, Zhenhuan
    Ren, Shan
    Ma, Lina
    Jin, Yi
    Zheng, Sujun
    Hu, Zhongjie
    Wang, Li
    Chen, Xinyue
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (17)
  • [45] Cost-Effectiveness of Hepatitis B Testing and Vaccination of Adults Seeking Care for Sexually Transmitted Infections
    Hutton, David W.
    Toy, Mehlika
    Salomon, Joshua A.
    Conners, Erin E.
    Nelson, Noele P.
    Harris, Aaron M.
    So, Samuel
    SEXUALLY TRANSMITTED DISEASES, 2022, 49 (07) : 517 - 525
  • [46] Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy
    Lui, Yanni Yan-Ni
    Tsoi, Kelvin Kam-Fai
    Wong, Vincent Wai-Sun
    Kao, Jia-Horny
    Hou, Jin-Lin
    Teo, Eng-Kiong
    Mohamed, Rosmawati
    Piratvisuth, Teerha
    Han, Kwang-Hyub
    Mihm, Ulrike
    Wong, Grace Lai-Hung
    Chan, Henry Lik-Yuen
    ANTIVIRAL THERAPY, 2010, 15 (02) : 145 - 155
  • [47] The independent impact of newborn hepatitis B vaccination on reducing HBV prevalence in China, 1992-2006: A mathematical model analysis
    Liang, Peifeng
    Zu, Jian
    Yin, Juan
    Li, Hao
    Gao, Longfei
    Cui, Fuqiang
    Wang, Fuzhen
    Liang, Xiaofeng
    Zhuang, Guihua
    JOURNAL OF THEORETICAL BIOLOGY, 2015, 386 : 115 - 121
  • [48] Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis
    Nayeri, Unzila A.
    Werner, Erika F.
    Han, Christina S.
    Pettker, Christian M.
    Funai, Edmund F.
    Thung, Stephen F.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 207 (03) : 231.e1 - 231.e7
  • [49] A preliminary cost-effectiveness analysis of hepatitis E vaccination among pregnant women in epidemic regions
    Zhao, Yueyuan
    Zhang, Xuefeng
    Zhu, Fengcai
    Jin, Hui
    Wang, Bei
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (08) : 2003 - 2009
  • [50] Immune persistence induced by three doses of 60 μg hepatitis B vaccine in non-responders following standard primary vaccination in Chinese adults
    Li, Juan
    Meng, Fanyue
    Zheng, Jingshan
    Liang, Qi
    Li, Huayu
    Li, Jingxin
    Zhang, Li
    Gan, Jianhui
    Zhu, Fengcai
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (08) : 2762 - 2767